Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical Cohort

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 3, 2016, Pages 280-286

  Berlowitz, David J ^a   Howard, Mark E ^a   Fiore, Julio F ^a   Van Der Hoorn, Stephen ^b   O'Donoghue, Fergal J ^a   Westlake, Justine ^a   Smith, Anna ^c   Beer, Fiona ^a   Mathers, Susan ^c   Talman, Paul ^c  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Bethlehem Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RILUZOLE;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BULBAR PARALYSIS; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE REGISTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; MOTOR NEURON DISEASE; NONINVASIVE VENTILATION; ONSET AGE; OVERALL SURVIVAL; PATIENT CODING; PATIENT SELECTION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHENOTYPE; PRACTICE GUIDELINE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SURVIVAL TIME; SYMPTOMATOLOGY; TRACHEOSTOMY; FACTUAL DATABASE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NONINVASIVE VENTILATION; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84930393227     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310055     Document Type: Article

References (31)

1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
2. Talman P, Forbes A, Mathers S. Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotrophic Lateral Sclerosis 2009;10:79-84.
3. Chio A, Calvo A, Moglia C, et al. Non-invasive ventilation in amyotrophic lateral sclerosis: a 10year population based study. J Neurol Neurosurg Psychiatry 2012;83:377-81.
4. Berlowitz DJ, Detering K, Schachter L. A retrospective analysis of sleep quality and survival with domiciliary ventilatory support in motor neuron disease. Amyotroph Lateral Scler 2006;7:100-6.
5. McDermott CJ, Shaw PJ. Diagnosis and management of motor neurone disease. BMJ 2008;336:658-62.
6. Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140-7.
7. O'Neill CL, Williams TL, Peel ET, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry 2012;83:371-6.
8. Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS-predictors of tolerance and survival. Neurology 2006;67:761-5.
9. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-303.
10. Olschewski M, Schumacher M, Davis KB. Analysis of randomized and nonrandomized patients in clinical trials using the comprehensive cohort follow-up study design. Control Clin Trials 1992;13:226-39.
11. Rothwell PM. Treating individuals 1-external validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 2005;365:82-93.
12. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
13. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1999;52:1311-23.
14. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
15. Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495-520.
16. American Thoracic Society/European Respiratory S. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166:518-624.
17. Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 2007;64:232-6.
18. Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310-23.
19. Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009;72:1087-94.
20. Kleopa KA, Sherman M, Neal B, et al. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164:82-8.
21. Sheers N, Berlowitz DJ, Rautela L, et al. Improved survival with an ambulatory model of non-invasive ventilation implementation in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:180-4.
22. Leonardis L, Groselj LD, Vidmar G. Factors related to respiration influencing survival and respiratory function in patients with amyotrophic lateral sclerosis: a retrospective study. Eur J Neurol 2012;19:1518-24.
23. Cnaan A, Ryan L. Survival analysis in natural history studies of disease. Stat Med 1989;8:1255-68.
24. Suissa S. Immortal Time Bias in Pharmacoepidemiology. Am J Epidemiol 2008;167:492-9.
25. Azzato EM, Greenberg D, Shah M, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates[quest]. Br J Cancer 2009;100:1806-11.
26. Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008;79:33-7.
27. del Aguila MA, Longstreth WT, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis-a population-based study. Neurology 2003;60:813-19.
28. Forbes RB, Colville S, Cran GW, et al. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. J Neurol Neurosurg Psychiatry 2004;75:1753-5.
29. Hill NS. Noninvasive positive pressure ventilation in neuromuscular disease. Enough is enough! Chest 1994;105:337-8.
30. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;(3): CD001447.
31. Garner DJ, Berlowitz DJ, Douglas J, et al. Home mechanical ventilation in Australia and New Zealand. Eur Respir J 2013;41:39-45.